September 26, 2017 : DCMS #364

SPECIAL FEATURE

Not All Neuropathies in Diabetes are Caused by Diabetes

EXCLUSIVE INTERVIEW — Candid Video Interviews with Top Practitioners

Osama Hamdy Part 1, Cultural Issues when Treating Diabetes

HOMERUN SLIDES — Great Clinical Presentation Highlights

Albuminuria: A Lot More Than Just a Little Protein in the Urine Part 7

CLINICAL GEMS — The Best from Diabetes Texts

International Textbook of Diabetes Mellitus, 4th Ed., Excerpt #93: Lipid and Lipoprotein Metabolism, Hypolipidemic Agents, and Therapeutic Goals Part 5

MOST POPULAR ARTICLES OF THE MONTH

#1 Type 1 Cured in Mice
#2 Is Sitting Really the New Smoking?
#3 EASD: First Oral Drug for Type 1 Diabetes – Tandem3 Study – Sotagliflozin

Over the past year, we have been following Team Novo Nordisk, the professional cycling team, as they travel the world and remind all of us that diabetes is not a disease that you cannot overcome. You can imagine that the cost of sponsoring a UCI team is very high. As an example, two of the teams that participated in the Tour de France have lost their sponsorship for the 2018 season.

This is why we at Diabetes in Control are pleased to let you know that Novo Nordisk has decided to sponsor the team for an additional two years. This commitment means that the team can continue their dream to race in the Tour de France.

Dave Joffe

Editor-in-chief

Global healthcare company Novo Nordisk, renewed its partnership with Team Novo Nordisk for an additional two years, extending the company’s commitment to the world’s first all-diabetes professional cycling team to a total of seven years.

In the conclusion of this Exclusive Interview, Drs. Sood and Messer talk with Diabetes in Control Publisher Steve Freed during the AACE 2017 convention in Austin, Texas about their individual diet philosophies and behavior modification.

In this week’s Homerun Slides, results of the HOPE trial and LIFE Study, and the main mediators that contribute to chronic kidney disease.

Therapeutic approaches to the dyslipidemia of insulin resistance and type 2 diabetes mellitus — Key points: The rationale for treating the diabetic dyslipidemia is clear, it is associated with significantly increased risk of cardiovascular events.Weight loss, exercise, and diet modifications are key to successful treatment of all of the lipid abnormalities in patients with T2DM. Statins are the mainstay of therapy—they lower LDL cholesterol up to 50%, lower triglycerides about 15–25%, and have minimal effects of HDL cholesterol levels.

Ralph DeFronzo and his researchers at UT Health at San Antonio announced that they have cured type 1 diabetes.

The evolution of metformin therapy through the decades.

Semaglutide trumps Trulicity in most recent trial.